(Q90928865)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

title

Biomaterial-assisted targeted modulation of immune cells in cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

author name string

Hua Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

publication date

13 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

page(s)

761-772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

17 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Immune Checkpoint Blockade in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Therapeutic vaccines for cancer: an overview of clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Cancer immunotherapy meets biomaterials

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Synthetic Nanoparticles for Vaccines and Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Biomaterials for enhancing anti-cancer immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Beyond antigens and adjuvants: formulating future vaccines

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Delivering safer immunotherapies for cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Cytokine-secreting tumor cell vaccines

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Overview of tumor cell-based vaccines

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Designer vaccine nanodiscs for personalized cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Programming the magnitude and persistence of antibody responses with innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A STING-activating nanovaccine for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Targeting Dendritic Cells in vivo for Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Dendritic cell targeted vaccines: Recent progresses and challenges

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Structure-based programming of lymph-node targeting in molecular vaccines

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Therapeutic vaccines and cancer: focus on DPX-0907.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Dendritic cell-derived exosomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Infection-mimicking materials to program dendritic cells in situ

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In situ regulation of DC subsets and T cells mediates tumor regression in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Biomaterial-based vaccine induces regression of established intracranial glioma in rats.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A facile approach to enhance antigen response for personalized cancer vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Polymer multilayer tattooing for enhanced DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Injectable, Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Injectable cryogel-based whole-cell cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A Protective Vaccine Delivery System for In Vivo T Cell Stimulation Using Nanoengineered Polymer Hydrogel Capsules

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Microneedles for drug and vaccine delivery

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A carbon nanotube-polymer composite for T-cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Microfluidic applications of magnetic particles for biological analysis and catalysis

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Biopolymer implants enhance the efficacy of adoptive T-cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In Vivo Enrichment of Diabetogenic T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Tumor-associated macrophages: from mechanisms to therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Macrophage plasticity and polarization: in vivo veritas

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Progress in tumor-associated macrophage (TAM)-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

The future of immune checkpoint therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41563-018-0147-9

7 January 2021

10.1038/S41563-018-0147-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30104668%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference